Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
HOME > REGULATORY
REGULATORY
- MHLW to Establish Task Force in Response to Scandal at Kaketsuken
December 16, 2015
- Diet Submission of Clinical Research Bill Expected for Next Year: Panel Member
December 15, 2015
- More than 10 Regenerative Medicine Products Seeking Sakigake Designation: MHLW Official
December 15, 2015
- Chuikyo Discusses Optimizing Health Coverage for Poultices, Vitamins
December 14, 2015
- PMDA Reviewing Use of Ofev in Patients with Liver Dysfunction
December 14, 2015
- LDP OKs Taxation Changes for FY2016; R&D Tax Credit to Remain Intact
December 11, 2015
- 6 Drug Makers to Participate in AMED’s Drug Discovery Consortium
December 11, 2015
- First Generics for Jzoloft, Other Brands to Join NHI Price List on Dec. 11
December 10, 2015
- 3 Trade Groups Vehemently Oppose “Huge Seller” Drug Re-Pricing, Say It Will Hobble Innovation
December 10, 2015
- Industry Opposes Expanded Price Cuts under Z2 Rule, Calls for Retention of 60% Pricing Rule for New Injectable, Topical Generics
December 10, 2015
- LDP Budget Debate in Homestretch; Govt Eyes “Huge Sellers”, Generics, Z2 to Squeak Out Funds for Upping Physician Fees
December 9, 2015
- MHLW’s Failure to Detect Kaketsuken’s 40-Year Cover-Up Regrettable: Shiozaki
December 9, 2015
- Editor’s Pick: Five Healthcare Policy News Headlines for November
December 8, 2015
- MHLW Announces Basic Policy for FY2016 Medical Fee Reform
December 8, 2015
- PMDA to Begin Unannounced Regular Inspections in Wake of GMP Violations by Kaketsuken
December 8, 2015
- MHLW Proposes Continuing Penalty Fee Cuts for Hospitals, Pharmacies with Revised Scope
December 7, 2015
- NHI-Market Price Gap of 8.8% Reported to Chuikyo; Generic Share at 56.2% in September
December 7, 2015
- MHLW Calls for 50% Pricing Rule for First Generics, 40% Rule for 10-Plus Oral Generics
December 4, 2015
- New HTA Scheme Should Only Cover Big-Selling Products Given Big Premiums: JPMA Chief
December 4, 2015
- Chuikyo Subcommittee Agrees on Scope of “Essential Drugs”; Trial Run of Innovation Premium to Continue
December 4, 2015
ページ
Global drug makers are forging ahead with therapies targeting lipoprotein(a), or Lp(a), a promising new approach to reducing cardiovascular risks.…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…